To investigate whether ANXA1 affected mice obesity via PPARγ in vivo, we treated HFD-fed Anxa1AKO mice with GW9662 (intraperitoneal injection every other day at a dose of 1 mg/kg for 16 weeks). Here, ANXA1 is linked to Obesity.